Brown Anna L, Arts Peer, Carmichael Catherine L, Babic Milena, Dobbins Julia, Chong Chan-Eng, Schreiber Andreas W, Feng Jinghua, Phillips Kerry, Wang Paul P S, Ha Thuong, Homan Claire C, King-Smith Sarah L, Rawlings Lesley, Vakulin Cassandra, Dubowsky Andrew, Burdett Jessica, Moore Sarah, McKavanagh Grace, Henry Denae, Wells Amanda, Mercorella Belinda, Nicola Mario, Suttle Jeffrey, Wilkins Ella, Li Xiao-Chun, Michaud Joelle, Brautigan Peter, Cannon Ping, Altree Meryl, Jaensch Louise, Fine Miriam, Butcher Carolyn, D'Andrea Richard J, Lewis Ian D, Hiwase Devendra K, Papaemmanuil Elli, Horwitz Marshall S, Natsoulis Georges, Rienhoff Hugh Y, Patton Nigel, Mapp Sally, Susman Rachel, Morgan Susan, Cooney Julian, Currie Mark, Popat Uday, Bochtler Tilmann, Izraeli Shai, Bradstock Kenneth, Godley Lucy A, Krämer Alwin, Fröhling Stefan, Wei Andrew H, Forsyth Cecily, Mar Fan Helen, Poplawski Nicola K, Hahn Christopher N, Scott Hamish S
Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia.
Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
Blood Adv. 2020 Mar 24;4(6):1131-1144. doi: 10.1182/bloodadvances.2019000901.
First reported in 1999, germline runt-related transcription factor 1 (RUNX1) mutations are a well-established cause of familial platelet disorder with predisposition to myeloid malignancy (FPD-MM). We present the clinical phenotypes and genetic mutations detected in 10 novel RUNX1-mutated FPD-MM families. Genomic analyses on these families detected 2 partial gene deletions, 3 novel mutations, and 5 recurrent mutations as the germline RUNX1 alterations leading to FPD-MM. Combining genomic data from the families reported herein with aggregated published data sets resulted in 130 germline RUNX1 families, which allowed us to investigate whether specific germline mutation characteristics (type, location) could explain the large phenotypic heterogeneity between patients with familial platelet disorder and different HMs. Comparing the somatic mutational signatures between the available familial (n = 35) and published sporadic (n = 137) RUNX1-mutated AML patients showed enrichment for somatic mutations affecting the second RUNX1 allele and GATA2. Conversely, we observed a decreased number of somatic mutations affecting NRAS, SRSF2, and DNMT3A and the collective genes associated with CHIP and epigenetic regulation. This is the largest aggregation and analysis of germline RUNX1 mutations performed to date, providing a unique opportunity to examine the factors underlying phenotypic differences and disease progression from FPD to MM.
种系 runt 相关转录因子 1(RUNX1)突变于 1999 年首次报道,是家族性血小板疾病伴髓系恶性肿瘤易感性(FPD-MM)的一个公认病因。我们展示了在 10 个新的 RUNX1 突变的 FPD-MM 家族中检测到的临床表型和基因突变。对这些家族的基因组分析检测到 2 个部分基因缺失、3 个新突变和 5 个复发性突变,这些是导致 FPD-MM 的种系 RUNX1 改变。将本文报道的家族基因组数据与汇总的已发表数据集相结合,得到了 130 个种系 RUNX1 家族,这使我们能够研究特定的种系突变特征(类型、位置)是否可以解释家族性血小板疾病患者与不同血液系统恶性肿瘤(HM)之间巨大的表型异质性。比较现有的家族性(n = 35)和已发表的散发性(n = 137)RUNX1 突变的急性髓系白血病(AML)患者的体细胞突变特征,发现影响第二个 RUNX1 等位基因和 GATA2 的体细胞突变富集。相反,我们观察到影响NRAS、SRSF2 和 DNMT3A 以及与 CHIP 和表观遗传调控相关的集体基因的体细胞突变数量减少。这是迄今为止对种系 RUNX1 突变进行的最大规模的汇总和分析,为研究从 FPD 到 MM 的表型差异和疾病进展的潜在因素提供了独特的机会。